ADMA Biologics Stock Drops 29% Amid Channel Stuffing Allegations
ADMA Biologics' stock price fell 29% following allegations of "channel stuffing" by Culper Research. A securities fraud class action lawsuit has been filed on behalf of investors.
ADMA Biologics experienced a significant 29% drop in its stock value after Culper Research published claims alleging the company engaged in "channel stuffing." This has prompted a securities fraud class action lawsuit filed on behalf of investors.
The allegations suggest that ADMA Biologics may have artificially inflated its sales figures by excessively increasing inventory levels at its distributors. Such practices, if proven, could mislead investors about the company's true sales performance and market demand.
The class action lawsuit asserts that the company and its management made materially false or misleading statements to the public, thereby violating federal securities laws. Investors who purchased ADMA Biologics stock are seeking damages resulting from this alleged misconduct.
ADMA Biologics has not yet issued a formal statement addressing the accusations. The legal proceedings will determine the validity of the claims and any potential liabilities for the company.